Development of antiarteriosclerosis medicines that reduced the risk of hepatotoxicity

Research Project

Project/Area Number	22790159
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	Medical pharmacy
Research Institution	Kyushu University
Principal Investigator	KUBOTA Toshio 九州大学, 薬学研究院, 准教授 (50533006)
Project Period (FY)	2010 – 2011
Project Status	Completed (Fiscal Year 2011)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	マクロファージ / 泡沫化 / スタチン / RDA R〕CKゲラニルゲラニルピロリン酸 / 動脈硬化 / RhoA/ROCK / ゲラニルゲラニルピロリン酸 / 薬学 / 脂質 / シグナル伝達
Research Abstract	Statins are the most widely used cholesterol-lowering agents. It is known that statins prevent arteriosclerosis. On the other hand, statins sometines influence the hepatic function The aimof this study is the comparison of molecular mechanism betwen anti arteriosclerosis effect and hapatotoxi ci ty by statins to develop and art eri oscl erosi s nEedi ci nes that reduced the ri sk of hepat otoxi ci ty. This study indicated the difference of the ifluence of statins against RhoA/ROOK